Guselkumab not checked
Johnson & Johnson (Janssen) · CNTO1959 · CNTO 1959
FollowEvery change as it happens, and a Monday email
Trials
28 active
59 in total · 28 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Guselkumab as prescribed by the participant's treating physician and obtained by the participant outside of the study per the treating physician's practice will be used.”In the company’s words, NCT07654751 on ClinicalTrials.gov
- Tested for
- Colitis, Ulcerative (6 trials), Arthritis, Psoriatic (5 trials), Crohn Disease (5 trials), Crohn's Disease (4 trials), Psoriasis (2 trials), Fistulizing Crohns Disease, Perianal Crohns Disease, Crohns Disease and 2 more
- Main trialPhase 4
- “The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.”In the company’s words, NCT04929210 on ClinicalTrials.gov
- Other names
- CNTO1959 · Tremfya · CNTO 1959
Other drugs for Colitis, Ulcerative
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up12
- 10 Feb 2027Phase 3 trial completes · ClinicalTrials.gov
- 25 Mar 2027Phase 3 trial completes · ClinicalTrials.gov
- 1 Apr 2027Phase 4 trial completes · ClinicalTrials.gov
- 5 Jun 2027Phase 4 trial completes · ClinicalTrials.gov
- 8 Jun 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2027Phase 4 trial completes · ClinicalTrials.gov
- 15 Sep 2027Phase 4 trial completes · ClinicalTrials.gov
- 27 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 12 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
- 11 Aug 2028Phase 3 trial completes · ClinicalTrials.gov
- 15 Nov 2028Phase 3 trial completes · ClinicalTrials.gov
- 12 Dec 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials59
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Active, not recruiting | 1 Apr 2027 | A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | |
| Phase 4Recruiting | 5 Jun 2027 | A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA) | |
| Phase 4Recruiting | 31 Aug 2027 | A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | |
| Phase 4Recruiting | 15 Sep 2027 | A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) | |
| Phase 3Active, not recruiting | 4 Jul 2023 | A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Active, not recruiting | 19 Jul 2023 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants | |
| Phase 3Active, not recruiting | 2 Apr 2024 | A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Active, not recruiting | 30 Dec 2024 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis | |
| Phase 3Active, not recruiting | 10 Feb 2027 | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Active, not recruiting | 25 Mar 2027 | A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | |
| Phase 3Active, not recruiting | 8 Jun 2027 | Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | |
| Phase 3Recruiting | 27 Oct 2027 | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 12 Jun 2028 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 11 Aug 2028 | A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Recruiting | 15 Nov 2028 | A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Recruiting | 12 Dec 2031 | A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants | |
| Phase 2/3Active, not recruiting | 19 Sep 2023 | A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2/3Active, not recruiting | 20 Oct 2023 | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 2Active, not recruiting | 15 May 2025 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Active, not recruiting | 23 May 2025 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 4Terminated | 28 Jul 2023 | Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 4Completed | 26 Sep 2023 | A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis | |
| Phase 3Completed | 29 Sep 2015 | A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis | |
| Phase 3Completed | 1 Oct 2015 | A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment | |
| Phase 3Completed | 28 Mar 2017 | An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis | |
| Phase 3Completed | 6 Feb 2018 | Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis | |
| Phase 3Completed | 25 Feb 2019 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis | |
| Phase 3Completed | 14 Mar 2019 | A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s) | |
| Phase 3Completed | 11 Nov 2020 | A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy | |
| Phase 3Completed | 2 Mar 2021 | A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis | |
| Phase 3Completed | 7 Mar 2022 | A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis | |
| Phase 3Terminated | 29 Sep 2023 | A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection | |
| Phase 3Completed | 29 Feb 2024 | A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 3Completed | 28 Oct 2024 | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | |
| Phase 3Completed | 14 Apr 2025 | Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis | |
| Phase 3Completed | 30 May 2025 | Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis | |
| Phase 3Completed | 12 Jan 2026 | A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis | |
| Phase 2Completed | 31 May 2016 | Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA) | |
| Phase 2Completed | 22 May 2020 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) | |
| Phase 2Completed | 1 Dec 2020 | A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Terminated | 1 Feb 2023 | A Study of Guselkumab in Participants With Active Lupus Nephritis | |
| Phase 2Completed | 17 May 2023 | A Study of Guselkumab in Participants With Systemic Sclerosis | |
| Phase 2Completed | 14 May 2024 | A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis | |
| Phase 2Terminated | 22 May 2024 | A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis | |
| Phase 1Completed | 12 Jan 2016 | A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants | |
| Phase 1Completed | 31 Dec 2020 | Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants | |
| Phase 1Completed | 20 Jul 2021 | A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants | |
| Phase 1Completed | 13 Sep 2021 | A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | |
| Phase 1Withdrawn | 13 Sep 2021 | A Study of Guselkumab in Adult Participants With Celiac Disease | |
| Phase 1Completed | 13 Sep 2021 | A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants | |
| Phase 1Terminated | 1 Jul 2022 | A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis | |
| Phase 4Authorised | not given | Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis | |
| Phase 4Authorised | not given | AN INVESTIGATOR-INITIATED, PHASE 4, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTER STUDY INVESTIGATING THE TISSUE-RESIDENT MEMORY T-CELLS AND DISEASE MEMORY IN PSORIASIS SKIN DURING GUSELKUMAB TREATMENT. THE GUSMEM STUDY. | |
| Phase 3Authorised | not given | A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis | |
| Phase 4Authorised | not given | Proactive therapeutic drug monitoring versus routine care with the novel biologics in psoriasis: a pragmatic, multicentric, randomised, controlled study (HELIOS) | |
| Phase 4Authorised | not given | Prospective, multicentre, open-label clinical trial on the effect of GUSelkumab on the resolution of ultrasound-proven ENThEsitis in patients with pSoriatic arthriTis | |
| Phase 4Authorised | not given | GUselkumAb inteRvention and DIet evaluAtioN for pouchitis | |
| Phase 4Authorised | not given | Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial. | |
| Phase 4Authorised | not given | OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026